INC Research, a global Phase I to IV contract research organization, announced an expanded relationship with the Society for Clinical Research Sites (SCRS) to become the society’s first Circle of Sustainability Sponsor. Through this enhanced relationship, INC Research will be the first organization to support SCRS’ new member Scholarship Program as well as the first CRO to establish a Site Advocacy Group (SAG). INC Research also will continue as a Global Impact Partner and Site Appreciation Reception sponsor for all SCRS’ Site Solutions Summit events globally across 2015.
Through the expanded relationship, INC Research will be the first CRO to establish a SAG, a new concept currently in use by TransCelerate BioPharma and Eli Lilly to facilitate ongoing dialogue with clinical investigators and site professionals worldwide in an effort to improve and drive efficiencies across the clinical development process. Through this approach, INC and investigative sites globally will exchange perspectives and insights on innovative methods, tools and technologies to enhance clinical research efficiency and more closely align the work of the sites and industry across the research ecosystem.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.